Abstract

Herpes simplex virus 2 (HSV-2) causes genital herpes and increases the risk of transmission and infection with HIV. Thus a vaccine for HSV-2 would not only reduce the rate of genital herpes, but also might reduce spread of HIV. Several HSV-2 vaccines have been tested in humans for prevention or reduction of genital herpes disease, but none has been licensed for use in humans. We completed a clinical trial of a replication-defective vaccine for HSV-2 termed HSV529. This vaccine can infect cells, but not replicate in the cells. We vaccinated three groups of 20 subjects with HSV529 (15 subjects per group) or saline placebo injection (5 subjects per group). The groups were a) subjects who were infected with HSV-2 in the past but may or may not have been infected with HSV-1 (HSV-1+/-/HSV-2+), (b) subjects who were infected only with HSV-1 (HSV-1+/HSV-2-), and (c) subjects who were not infected with HSV-1 or HSV-2 (HSV-1-/HSV-2-). Each subject was followed after vaccination and safety and immune responses to the vaccine were studied. The data from the study are currently being evaluated.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI000548-30
Application #
9786301
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
30
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Cohen, Jeffrey I (2018) Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-? Syndrome. Front Immunol 9:237
Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan et al. (2017) Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice J Virol 91:
Cohen, Jeffrey I (2017) Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2. J Infect Dis 215:844-846
Odegard, Jared M; Flynn, Patrick A; Campbell, David J et al. (2016) A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine 34:101-9
Wang, Kening; Goodman, Kyle N; Li, Daniel Y et al. (2016) A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. J Virol 90:562-74
Lamers, Susanna L; Newman, Ruchi M; Laeyendecker, Oliver et al. (2015) Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. J Virol 89:8206-18
Çuburu, Nicolas; Wang, Kening; Goodman, Kyle N et al. (2015) Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. J Virol 89:83-96
Newman, Ruchi M; Lamers, Susanna L; Weiner, Brian et al. (2015) Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol 89:8219-32
Knipe, David M; Corey, Lawrence; Cohen, Jeffrey I et al. (2014) Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on ""Next Generation Herpes Simplex Virus Vaccines"". Vaccine 32:1561-2
Ben-Sasson, S Z; Wang, K; Cohen, J et al. (2013) IL-1? strikingly enhances antigen-driven CD4 and CD8 T-cell responses. Cold Spring Harb Symp Quant Biol 78:117-24

Showing the most recent 10 out of 15 publications